Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 10;78(4):1005-1010.
doi: 10.1093/cid/ciad695.

Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection

Antoine Bachelard  1 , Quentin Le Hingrat  2   3 , Valentine-Marie Ferré  2   3 , Minh Lê  4 , Gilles Peytavin  3   4 , Florence Damond  2   3 , Charlotte Charpentier  2   3 , Guillemette Fremont Goudot  5 , Jeanne Goupil de Bouille  6 , Sylvie Lariven  1 , Pierre Delobel  7   8 , Yazdan Yazdanpanah  1   3 , Diane Descamps  2   3 , Sophie Matheron  1   3 , Jade Ghosn  1   3 ; ANRS CO05 VIH-2 cohort study group
Collaborators, Affiliations

Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection

Antoine Bachelard et al. Clin Infect Dis. .

Abstract

We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.

Keywords: HIV-2; foscarnet; ibalizumab; multi-drug resistance; salvage therapy.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. J. G. reports receiving support as an advisor for Gilead Sciences, MSD, Roche, Astra-Zeneca, Theratechnologies and ViiV. S. L. and G. F. G. report receiving support for attending medical conferences from Gilead. D. D. reports grants or contracts, honoraria as an advisor, and support for attending medical conferences from ViiV, Gilead and MSD. V.-M. F. reports payment or honoraria for speaking engagements from Astra-Zeneca and Moderna; travel support from Gilead, and receiving equipment, materials, drugs or other services from Copan. C. C. reports receiving honoraria as an advisor and support for attending medical conferences from MSD, Gilead, and ViiV. G. P. reports receiving grants or contracts from Gilead Sciences, ViiV Healthcare, Merck France, and Takeda; consulting fees from Gilead Sciences and ViiV Healthcare; payment for speaking engagements from Gilead Sciences and ViiV Healthcare; travel support from Gilead Sciences; and payment for Advisory of Data Safety Monitoring Board participation from Gilead Sciences and ViiV Healthcare. P. D. and S. M. report an unpaid role for French guidelines for antiretroviral therapy (HAS, ANRS, CNS). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

Publication types